Why do the latest guidelines on the treatment of hypertension (PTNT 2015) indicate that telmisartan, as an exception among ARBs, should be the drug of choice in patients with hypertension and multiple cardiovascular risk factors:

Marek  Chmielewski; Marek  Kuch

PDF

Published: Mar 31, 2016

Keywords:

hypertension, cardiovascular risk, ARB, telmisartan

Marek Chmielewski

Department and Clinic of Cardiology, Arterial Hypertension and Internal Medicine, Second Faculty of Medicine, Medical University of Warsaw

Marek Kuch

Department and Clinic of Cardiology, Arterial Hypertension and Internal Medicine, Second Faculty of Medicine, Medical University of Warsaw

Abstract

The efficacy of telmisartan for cardiovascular prevention in high-risk patients has been confirmed in the ONTARGET study. Telmisartan is as efficacious as ACE inhibitors (ramipril), which has ensured its high position in the current PTNT recommendations (2015).

How to Cite

Chmielewski , M., & Kuch, M. (2016). Why do the latest guidelines on the treatment of hypertension (PTNT 2015) indicate that telmisartan, as an exception among ARBs, should be the drug of choice in patients with hypertension and multiple cardiovascular risk factors. Medycyna Faktow (J EBM), 9(1(30), 30-31. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2264

Issue

Vol 9 No 1(30) (2016)

Section

Articles

References

1. HOPE Study Investigators. N Engl J Med 2000; 342: 145-153.
2. The ONTARGET Investigators. N Engl J Med 2008; 358: 1547-1559.
3. Management of Arterial Hypertension. 2015 Guidelines of the Polish Society of Arterial Hypertension; 1(1): 1-70.

Article Sidebar

Main Article Content

Abstract

Article Details

References